156 related articles for article (PubMed ID: 23221048)
1. [Recent progress in research of colorectal cancer].
Inoue M
Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2007-13. PubMed ID: 23221048
[No Abstract] [Full Text] [Related]
2. Maintenance therapy in metastatic colorectal cancer.
Marshall JL
Clin Adv Hematol Oncol; 2014 Jun; 12(6):388-90. PubMed ID: 25003569
[No Abstract] [Full Text] [Related]
3. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
Satoh T
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
[No Abstract] [Full Text] [Related]
4. [Reception and adjuvant chemotherapy for metastatic site of colorectal cancer].
Nakamura M
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1381-6. PubMed ID: 25577807
[No Abstract] [Full Text] [Related]
5. Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents.
Liu X; Ji Q; Fan Z; Li Q
Future Oncol; 2015; 11(21):2911-22. PubMed ID: 26414153
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.
Caiazza F; Elliott L; Fennelly D; Sheahan K; Doherty GA; Ryan EJ
Biomark Med; 2015; 9(4):363-75. PubMed ID: 25808440
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
8. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Goldberg R
Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664
[No Abstract] [Full Text] [Related]
9. [New molecular targeting drugs for metastatic colorectal cancer].
Komatsu Y; Harada K; Fukushima H; Yuki S
Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
[TBL] [Abstract][Full Text] [Related]
10. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients.
Puzzoni M; Ziranu P; Demurtas L; Lai E; Mariani S; Liscia N; Soro P; Pretta A; Impera V; Camera S; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Scartozzi M
Future Oncol; 2020 Jan; 16(2):4337-4339. PubMed ID: 31793396
[No Abstract] [Full Text] [Related]
11. Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.
Ribecco AS; Pino MS; Cipriani G; Marinozzi C; Fioretto L
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1181-91. PubMed ID: 24134420
[TBL] [Abstract][Full Text] [Related]
12. [Issues of molecular targeted therapies in combination with chemotherapy in metastatic colorectal cancer].
Asayama M; Kadowaki S; Yamaguchi K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():464-71. PubMed ID: 22214005
[No Abstract] [Full Text] [Related]
13. Targeted therapy in colorectal cancer: current status and future challenges.
Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
[TBL] [Abstract][Full Text] [Related]
14. Colorectal clinical trials: what is on the horizon?
Ahn DH; Goldberg RM
Future Oncol; 2016 Feb; 12(4):525-31. PubMed ID: 26777152
[TBL] [Abstract][Full Text] [Related]
15. Testing for RAS mutations in patients with metastatic colorectal cancer.
Lenz HJ
Clin Adv Hematol Oncol; 2014 Jan; 12(1):48-9. PubMed ID: 25000315
[No Abstract] [Full Text] [Related]
16. [Efficacy of monoclonal antibodies in combination with chemotherapy in metastatic colorectal cancer].
Takiuchi H
Nihon Rinsho; 2011 Apr; 69 Suppl 3():459-63. PubMed ID: 22214004
[No Abstract] [Full Text] [Related]
17. Options for patients with metastatic colorectal cancer who progress after second-line therapy.
Marshall JL
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):2-4. PubMed ID: 31730589
[No Abstract] [Full Text] [Related]
18. The changing face of treatment for metastatic colorectal cancer.
Pfeiffer P; Köhne CH; Qvortrup C
Expert Rev Anticancer Ther; 2019 Jan; 19(1):61-70. PubMed ID: 30381969
[No Abstract] [Full Text] [Related]
19. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways.
Lemos C; Sack U; Schmid F; Juneja M; Stein U
Curr Pharm Des; 2013; 19(5):841-63. PubMed ID: 22973955
[TBL] [Abstract][Full Text] [Related]
20. Netrin-1 as a potential target for metastatic cancer: focus on colorectal cancer.
Ko SY; Blatch GL; Dass CR
Cancer Metastasis Rev; 2014 Mar; 33(1):101-13. PubMed ID: 24338005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
